Artelo Biosciences Announces $9.475 Million At-the-Market Private Placement to Initiate Solana Treasury Strategy, Becoming First Publicly-Traded Pharmaceutical Company to Adopt SOL as a Core Reserve Asset
Artelo Biosciences (Nasdaq: ARTL) has secured a $9.475 million private placement to implement a groundbreaking Solana (SOL) treasury strategy, becoming the first publicly-traded pharmaceutical company to adopt SOL as a core reserve asset. The financing includes the sale of 906,687 shares at $10.45 per share, along with two sets of three-year warrants.
The placement brings total proceeds since June 2025 to $10.9 million. Lead investor Bartosz Lipiński, former Head of Engineering at Solana Labs and Metaplex inventor, will serve as a technical partner through his company CUBE. The Board has approved expanding the SOL treasury strategy over time while maintaining adequate working capital for therapeutic development.
The private placement is expected to close around August 5, 2025, with R.F. Lafferty & Co. serving as advisor.
Artelo Biosciences (Nasdaq: ARTL) ha ottenuto un private placement da 9,475 milioni di dollari per implementare una strategia innovativa di tesoreria basata su Solana (SOL), diventando la prima società farmaceutica quotata in borsa ad adottare SOL come asset di riserva principale. Il finanziamento prevede la vendita di 906.687 azioni a 10,45 dollari per azione, insieme a due serie di warrant triennali.
Il collocamento porta il totale dei proventi da giugno 2025 a 10,9 milioni di dollari. L'investitore principale, Bartosz Lipiński, ex Responsabile Ingegneria di Solana Labs e inventore di Metaplex, agirà come partner tecnico tramite la sua azienda CUBE. Il Consiglio di Amministrazione ha approvato l'espansione graduale della strategia di tesoreria SOL, garantendo al contempo un capitale operativo adeguato per lo sviluppo terapeutico.
Il private placement dovrebbe concludersi intorno al 5 agosto 2025, con R.F. Lafferty & Co. come consulente.
Artelo Biosciences (Nasdaq: ARTL) ha asegurado una colocación privada de 9,475 millones de dólares para implementar una innovadora estrategia de tesorería con Solana (SOL), convirtiéndose en la primera empresa farmacéutica que cotiza en bolsa en adoptar SOL como activo principal de reserva. La financiación incluye la venta de 906,687 acciones a 10.45 dólares por acción, junto con dos series de warrants a tres años.
La colocación eleva los ingresos totales desde junio de 2025 a 10.9 millones de dólares. El inversor principal, Bartosz Lipiński, ex Jefe de Ingeniería en Solana Labs e inventor de Metaplex, actuará como socio técnico a través de su empresa CUBE. La Junta ha aprobado expandir la estrategia de tesorería SOL con el tiempo, manteniendo al mismo tiempo un capital de trabajo suficiente para el desarrollo terapéutico.
Se espera que la colocación privada se cierre alrededor del 5 de agosto de 2025, con R.F. Lafferty & Co. como asesor.
아텔로 바이오사이언스 (나스닥: ARTL)는 혁신적인 솔라나(SOL) 재무 전략을 실행하기 위해 947만 5천 달러의 사모 발행을 확보했으며, SOL을 핵심 준비 자산으로 채택한 최초의 상장 제약 회사가 되었습니다. 이번 자금 조달은 906,687주를 주당 10.45달러에 판매하고, 3년 만기 워런트 두 세트를 포함합니다.
이번 발행으로 2025년 6월 이후 총 조달 금액은 1090만 달러에 달합니다. 주요 투자자인 바르토시 리핀스키는 솔라나 랩스의 전 엔지니어링 책임자이자 메타플렉스 발명가로서, 그의 회사 CUBE를 통해 기술 파트너로 참여합니다. 이사회는 치료제 개발을 위한 충분한 운전자본을 유지하면서 SOL 재무 전략을 점진적으로 확대하는 것을 승인했습니다.
사모 발행은 2025년 8월 5일경에 마감될 예정이며, R.F. Lafferty & Co.가 자문을 맡습니다.
Artelo Biosciences (Nasdaq : ARTL) a obtenu un placement privé de 9,475 millions de dollars pour mettre en œuvre une stratégie novatrice de trésorerie basée sur Solana (SOL), devenant ainsi la première société pharmaceutique cotée en bourse à adopter SOL comme actif de réserve principal. Le financement comprend la vente de 906 687 actions au prix de 10,45 dollars par action, ainsi que deux séries de bons de souscription d’actions d’une durée de trois ans.
Ce placement porte le produit total depuis juin 2025 à 10,9 millions de dollars. L’investisseur principal, Bartosz Lipiński, ancien responsable de l’ingénierie chez Solana Labs et inventeur de Metaplex, agira en tant que partenaire technique via sa société CUBE. Le conseil d’administration a approuvé l’extension progressive de la stratégie de trésorerie SOL tout en maintenant un fonds de roulement adéquat pour le développement thérapeutique.
Le placement privé devrait se clôturer aux alentours du 5 août 2025, avec R.F. Lafferty & Co. en tant que conseiller.
Artelo Biosciences (Nasdaq: ARTL) hat eine Privatplatzierung in Höhe von 9,475 Millionen US-Dollar gesichert, um eine bahnbrechende Solana (SOL)-Treasury-Strategie umzusetzen und ist damit das erste börsennotierte Pharmaunternehmen, das SOL als Kernreservevermögen einführt. Die Finanzierung umfasst den Verkauf von 906.687 Aktien zu je 10,45 US-Dollar sowie zwei Serien von dreijährigen Warrants.
Die Platzierung bringt die Gesamterlöse seit Juni 2025 auf 10,9 Millionen US-Dollar. Hauptinvestor Bartosz Lipiński, ehemaliger Leiter der Technik bei Solana Labs und Erfinder von Metaplex, wird über sein Unternehmen CUBE als technischer Partner fungieren. Der Vorstand hat die schrittweise Ausweitung der SOL-Treasury-Strategie genehmigt und dabei ausreichendes Betriebskapital für die therapeutische Entwicklung sichergestellt.
Die Privatplatzierung soll um den 5. August 2025 abgeschlossen werden, wobei R.F. Lafferty & Co. als Berater fungiert.
- Strategic diversification of treasury through SOL cryptocurrency adoption
- Secured significant funding of $9.475M through private placement
- Partnership with prominent Solana ecosystem leader Bartosz Lipiński
- Total proceeds of $10.9M raised since June 2025
- Board approval for expansion of SOL treasury strategy
- Potential shareholder dilution from new share issuance
- Exposure to cryptocurrency market volatility through SOL holdings
- Significant warrant overhang with two sets of three-year warrants
Insights
Artelo's $9.475M raise to adopt Solana as a reserve asset represents an unconventional treasury strategy with significant risk/reward potential for a clinical-stage biotech.
Artelo Biosciences has secured
What makes this financing unusual is Artelo's stated intention to use these proceeds to launch a Solana (SOL) cryptocurrency treasury strategy, positioning themselves as the first publicly-traded pharmaceutical company to adopt SOL as a reserve asset. This represents a dramatic departure from conventional biotech treasury management approaches, which typically prioritize cash preservation through low-risk instruments.
The move appears strategically supported by bringing on Bartosz Lipiński, former Head of Engineering at Solana Labs and Metaplex inventor, as lead investor and technical advisor. His expertise in Solana's ecosystem could provide Artelo with specialized guidance in navigating digital asset management, though pharmaceutical development remains fundamentally disconnected from cryptocurrency operations.
For investors, this represents a significant transformation in Artelo's risk profile. While the company maintains its clinical-stage pharmaceutical focus on lipid-signaling pathways, allocating capital to volatile cryptocurrency assets introduces substantial financial variability that would normally be avoided by pre-revenue biotechs. The board's approval for expanding this SOL treasury strategy over time suggests this is not merely a one-time allocation but a fundamental shift in financial philosophy.
Notably, the financing structure – with high-strike warrants at
Artelo's pioneering move to integrate Solana into its treasury represents a watershed moment in corporate treasury management, particularly for clinical-stage biopharmaceutical companies. Traditional treasury strategies in pre-commercial biotech typically emphasize capital preservation through ultra-conservative instruments, making this cryptocurrency adoption exceptionally unorthodox.
The strategic partnership with Bartosz Lipiński carries particular significance. As Metaplex's inventor and former Solana Labs engineering lead, Lipiński brings elite-level Solana ecosystem expertise that would be otherwise inaccessible to a pharmaceutical company. His involvement suggests this isn't merely a speculative position but potentially a sophisticated treasury strategy leveraging Solana's DeFi capabilities.
The press release specifically mentions "staking and active DeFi execution" through CUBE, indicating Artelo intends to generate yield on these assets rather than simply holding SOL as a static reserve. This approach could potentially generate operating capital through yield farming, validator rewards, and other DeFi mechanisms – creating a perpetual funding stream if executed successfully.
However, this strategy introduces substantial new risk vectors that pharmaceutical investors rarely encounter: smart contract vulnerabilities, protocol governance changes, regulatory uncertainty, and extreme price volatility. The pharmaceutical development timeline – often spanning 7-10 years through clinical trials – traditionally demands predictable capital resources, making cryptocurrency exposure potentially misaligned with core business needs.
For Solana's ecosystem, having a Nasdaq-listed pharmaceutical company adopt SOL represents institutional validation that extends beyond typical financial sector adoption. This cross-industry penetration could potentially influence other biotech firms to consider similar treasury diversification strategies, particularly if Artelo demonstrates sustainable capital formation through this approach.
Lead investor Bartosz Lipiński, previously Head of Engineering at Solana Labs, will serve as a technical partner
CUBE selected to secure storage, staking, and active DeFi execution of Artelo’s digital asset treasury
Artelo’s Board approves authorization to expand Company’s SOL treasury management strategy over time
SOLANA BEACH, Calif., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological or neurological conditions, today announced that it has entered into a securities purchase agreement for an at-the market PIPE (private investment in public equity) for the purchase and sale of securities at a price of
The Company intends to use the proceeds to launch its Solana (“SOL”)-centric digital asset treasury strategy, as well as to support Artelo’s ongoing business. Artelo’s treasury initiative marks a pivotal step in its long-term growth strategy, as it becomes the first publicly traded pharmaceutical company to adopt SOL—Solana’s native cryptocurrency—as a reserve asset. This move signals Artelo’s commitment to forward-thinking financial management and positions the Company at the intersection of biotechnology innovation and decentralized finance. By integrating SOL into its balance sheet, Artelo diversifies its treasury while gaining exposure to a next-generation monetary network that complements traditional cash management.
Widely recognized as the inventor of Metaplex, SOL’s core NFT protocol that powered the ecosystem’s explosive growth in digital assets, Bartosz Lipiński is the lead investor for the launch of Artelo’s SOL treasury strategy and will serve as a technical advisor and a partner through his company CUBE.
“I am pleased to partner with Artelo for their groundbreaking SOL treasury initiative within the pharmaceutical industry,” said Bartosz Lipiński, Co-Founder and CEO of Cube Group. “Solana’s unparalleled scalability and decentralized infrastructure make it a cornerstone of the future financial ecosystem. By adopting SOL as a treasury asset, Artelo is positioning itself for sustainable growth and resilience, leveraging a cutting-edge monetary network to enhance shareholder value. I am confident this strategic move will yield significant long-term benefits for both Artelo and the broader Solana ecosystem.”
Artelo’s Board has also approved the expansion of the Company’s SOL treasury strategy, based on staged investments over time, while keeping adequate working capital for the continued development and commercialization of its proprietary therapeutics.
“We are excited to commence our SOL treasury strategy,” said Gregory D. Gorgas, Chief Executive Officer of Artelo Biosciences. “This initiative reflects our commitment to innovative and disciplined capital management while taking a strategic step into the digital asset space. By integrating SOL into our treasury, we aim to enhance long-term value for shareholders through thoughtful exposure to one of the most decentralized and scalable digital assets in the market. We believe this approach positions Artelo at the forefront of such financial treasury strategies within the biotech sector, demonstrating forward-thinking leadership in an evolving capital landscape.”
The closing of the PIPE is expected to occur on or about August 5, 2025, subject to the satisfaction of customary closing conditions. R. F. Lafferty & Co., Inc. acted as an advisor in connection with the PIPE.
The offer and sale of the foregoing securities is being made in a private placement in reliance on an exemption from the registration requirement of the Securities Act of 1933, as amended (the “Securities Act”), pursuant to Section 4(a)(2) of the Securities Act and/or Regulation D promulgated thereunder, and applicable state securities laws. Accordingly, the securities offered in the private placement may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirement of the Securities Act and such applicable state securities laws. The securities purchase agreement contains a registration rights covenant pursuant to which the Company has agreed to file a registration statement with the Securities and Exchange Commission (the “SEC”) registering the resale of the shares of common stock, and the shares of common stock underlying the warrants sold in the offering. Any offering of the securities under the resale registration statement will only be made by means of a prospectus.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
The private placement is being conducted in accordance with applicable Nasdaq rules and was priced to satisfy the "Minimum Price" requirement (as defined in the Nasdaq rules).
About SOL
Launched in 2020 by Anatoly Yakovenko and the Solana team, Solana is a high-performance, peer-to-peer blockchain engineered for speed, security, and decentralization. Its native token, SOL, powers a network that is transforming the landscape of internet capital markets by providing the infrastructure for seamless, global financial interactions. Solana enables the tokenization of real-world assets, high-frequency decentralized trading, and innovative DeFi protocols, creating an open, borderless system where capital can flow efficiently without traditional intermediaries. This positions Solana as the backbone for the next era of digital finance, where anyone with internet access can participate in sophisticated markets at minimal cost.
Solana's traction eclipses that of other blockchains, as evidenced by key metrics: it boasts over 3.25 million daily active users and processes 35.99 million daily transactions, far outpacing Ethereum's 410,000+ daily active users and 1.13 million daily transactions. The network's Total Value Locked (TVL) has reached
About Cube
Cube Exchange is a hybrid crypto trading platform revolutionizing digital asset markets through proprietary infrastructure that delivers trades up to 40 times faster than the industry average. Powered by an advanced MPC (multi-party computation) wallet system, Cube puts users in control of their assets while maintaining institutional-grade security. Traders can seamlessly execute strategies across desktop, mobile, and even Telegram—wherever they are, whenever they want. In addition to its award-winning retail offering, Cube provides a high-performance institutional platform designed for professional trading firms, corporate crypto treasuries, and funds seeking speed, secure storage, and execution at scale. Learn more at www.cube.exchange
About Artelo Biosciences
Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company dedicated to the development and commercialization of proprietary therapeutics that modulate lipid-signaling pathways, with a diversified pipeline addressing significant unmet needs in anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation. Complementing its scientific innovation, Artelo has adopted a forward-looking corporate finance initiative whereby it is deploying a portion of its excess capital into Solana (SOL) under a newly authorized digital asset treasury strategy. As the first publicly traded pharmaceutical company to designate SOL as a core reserve asset, Artelo intends to leverage Solana’s high-performance, decentralized blockchain to diversify its balance sheet, enhance liquidity management, and position the Company for long-term value creation in parallel with its therapeutic programs. Guided by disciplined risk controls and staged investments approved by the Board of Directors, this SOL-centric strategy is designed to preserve working capital for the continued advancement and commercialization of Artelo’s product candidates while affording shareholders exposure to a next-generation monetary network. Led by an experienced executive team collaborating with world-class researchers and digital-asset technology partners, Artelo applies rigorous scientific, regulatory, commercial, and treasury management practices to maximize stakeholder value. More information is available at www.artelobio.com and X: @ArteloBio.
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s future investment policy of its excess capital, product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions. These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission, including our ability to raise additional capital in the future. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by applicable securities laws.
Investor Relations Contact:
Crescendo Communications, LLC
Tel: 212-671-1020
Email: ARTL@crescendo-ir.com
FAQ
What is the size and structure of Artelo Biosciences (ARTL) private placement announced in August 2025?
Why is Artelo Biosciences adopting Solana (SOL) as a reserve asset?
Who is the lead investor in Artelo's SOL treasury initiative?
How will Artelo Biosciences implement its SOL treasury strategy?
What is the total amount raised by Artelo Biosciences since June 2025?
